1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one
• 英文别名: Caplyta；1-(4-fluorophenyl)-4-(4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl)butan-1-one
• 化学式: C₂₄H₂₈FN₃O
• 分子量: 393.504
• InChiKey: HOIIHACBCFLJET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  26.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline 、 4'-氟-4-碘苯丁酮 在 caesium carbonate 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以69.93%的产率得到1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one
  参考文献：
  名称：

  WO2022/73470

  摘要：

  公开号：

文献信息

• [EN] METHOD FOR THE MANUFACTURE OF LUMATEPERONE AND ITS SALTS<br/>[FR] PROCÉDÉ POUR LA FABRICATION DE LUMATÉPÉRONE ET DE SES SELS
  申请人：EGYT GYOGYSZERVEGYESZETI GYAR

  公开号：WO2019102240A1

  公开（公告）日：2019-05-31

  Method for the production of formula (I) lumateperone or its acid addition salts so that the enantiomer compound with stereochemistry 6bR, 10aS is separated form the cis racemate using resolution and the formula (II) stereoisomer is alkylated with 4-halo-4'-fluoro butyrophenone (X = I, Br, CI) to produce the formula (I) lumateperone, or optionally its acid addition salt. The object of the invention also relates to the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone and to the naphthalene-2-sulfonic acid salt of lumateperone, to the 1 :2 stoichiometry salt of lumateperone formed with naphthalene-2-sulfonic acid.

  生产配方（I）卢马特贝隆或其酸盐的方法，以便通过分辨法将立体化学为6bR，10aS的对映异构体与顺式混合物分离，使用配方（II）立体异构体与4-卤代-4'-氟丁酮苯（X = I，Br，Cl）烷基化，制备配方（I）卢马特贝隆，或可选择其酸盐。本发明的目的还涉及卢马特贝隆形态上均匀的对甲苯磺酸盐和卢马特贝隆的萘-2-磺酸盐，以及与萘-2-磺酸形成的1：2化学计量比的卢马特贝隆盐。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：INTRA CELLULAR THERAPIES INC

  公开号：WO2018126143A1

  公开（公告）日：2018-07-05

  The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.

  该发明涉及特定的取代杂环融合γ-咔啉，它们的前药，以及在本文中描述的自由、固体、药用盐和/或基本纯净形式，以及其药用组合物，以及在治疗涉及5-HT2A受体、5-羟色胺转运体（SERT）、涉及多巴胺D1和D2受体信号系统的途径和/或μ-阿片受体的疾病中的使用方法。
• [EN] ORGANIC COMPOUND<br/>[FR] COMPOSÉ ORGANIQUE
  申请人：INTRA CELLULAR THERAPIES INC

  公开号：WO2021119334A1

  公开（公告）日：2021-06-17

  The invention relates to a particular substituted heterocycle fused gamma-carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

  本发明涉及一种特定的取代杂环融合的γ-咔啉化合物，化合物的化学式为I，以及与此相关的新方法和用途，以及其制备的药物组合物，如用于治疗涉及5-HT受体、血清素转运体（SERT）和/或多巴胺D2受体信号通路、钠通道活性和/或去甲肾上腺素转运体活性的疾病的使用方法。
• 5-HT2A SEROTONIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR USE IN REDUCING AMYLOID-BETA PEPTIDES AND ACCUMULATION OF AMYLOID PLAQUES
  申请人：Acadia Pharmaceuticals Inc.

  公开号：EP3436010A1

  公开（公告）日：2019-02-06
• SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF
  申请人：TEVA CZECH INDUSTRIES S.R.O

  公开号：US20220024924A1

  公开（公告）日：2022-01-27

  The present disclosure relates to solid state forms of Lumateperone besylate and Lumateperone tosylate:R-(−)-mandelic acid, to various intermediates, to processes for their preparation and the preparation of Lumateperone or salt thereof, to pharmaceutical compositions and their use for the treatment of central nervous system disorders.